Abstract 151P
Background
Depth of response (DpR) and early tumor shrinkage (ETS) are established predictors of overall survival (OS) in colorectal and gastric cancer; however, data for pancreatic cancer (PC) are limited.
Methods
This study was conducted as part of two multicenter retrospective studies (NAPOLEON and NAPOLEON-2) of patients (pts) with measurable advanced PC tumors. Cohort 1 included 292 pts treated with gemcitabine/nab-PTX (GnP, 184 pts) and FOLFIRINOX (FFX, 108 pts) as first-line chemotherapy, and Cohort 2 included 88 pts treated with nanoliposomal irinotecan, fluorouracil and folinic acid as second-line chemotherapy. DpR was defined as the maximum tumor shrinkage percentage on imaging compared with the pre-treatment level. Pts were divided by DpR into three groups: control (Group A), responder (Group B), and deep responder (Group C). ETS was defined as ≥20% reduction from the start of treatment to the second evaluation.
Results
In Cohort 1, DpR was −2.3 to +1550% in Group A, −28.6 to −2.5% in Group B, and −100.0 to −28.6% in Group C. The baseline C-reactive protein/albumin ratio differed significantly by group (p=0.04). The median OS (mOS) was significantly longer in Group C (17.2 months) and Group B (11.5 months) than in Group A (8.4 months), (hazard ratio [HR], 95% confidence interval [CI]: 0.30, 0.22–0.42, p<0.01; and 0.58, 0.43–0.79, p<0.01, respectively). The mOS was also significantly longer in the ETS group overall (HR 0.46, 95% CI 0.35–0.61, p<0.01) and in both the GnP and FFX subgroups. In Cohort 2, DpR was +18.4 to +128.6% in Group A, −2.9 to +17.9% in Group B, and −80.0 to −3.2% in Group C. The baseline prevalence of ascites differed significantly by group (p=0.04). The mOS was significantly longer in Group C (10.9 months) than in Group A (4.6 months; HR 0.33, 95% CI 0.17–0.65, p<0.01), but mOS in Group B (6.8 months) did not differ significantly from Group A (p=0.10).
Conclusions
This is the first report that DpR and ETS might be predictors of OS in pts with PC on standard chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract